March 30, 2017 / 1:06 AM / 8 months ago

BRIEF-Starpharma complates Vivagel BV phase 3 trials

March 30 (Reuters) - Starpharma Holdings Ltd

* Vivagel BV phase 3 trials for prevention of BV completed

* Starpharma expects topline results of trials to be available in Q2 of 2017

* Has been granted a special protocol agreement by FDA which provides company with binding FDA agreement on trial design including primary endpoint Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below